Medical Tidbits,Experimental Immunotherapy Zaps Two Most Lethal Ebola Virus Strains

the-lithovue-system-4-HR

BRONX, N.Y., Jan. 13, 2016 /PRNewswire-USNewswire/ — Researchers at Albert Einstein College of Medicineand the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. The findings, made in mice, are a significant step toward immunotherapies that are effective against all strains of Ebola virus that cause human disease. The study was published online today in Scientific Reports. read more

Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib

MECHELEN, Belgium & FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 13, 2016– Galapagos NV (Euronext & NASDAQ:GLPG) and Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Federal Trade Commission provided early termination of the waiting period for the global partnership agreement on filgotinib under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The deal is expected to close by the end of the month. – read more

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B

— High Rates of Viral Suppression and Improved Renal and Bone Safety Parameters Compared to Viread in Phase 3 Studies — FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 12, 2016– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tenofovir alafenamide (TAF) 25 mg, an investigational, once-daily treatment for adults with chronic hepatitis B virus (HBV) infection. TAF is a novel, targeted prodrug of tenofovir that has demonstrated high antiviral efficacy similar to and at a dose less than one-tenth that of Gilead’s Viread® (tenofovir disoproxil fumarate, TDF), as well as improvements in surrogate laboratory markers of renal and bone safety as compared to Viread. – read more

Stryker Provides 2015 Preliminary Sales Results and Increases Adjusted Earnings Guidance

Preliminary net sales for the fourth quarter and full year 2015 were $2.7 billion and $9.9 billion, respectively, increases of 3.7% and 2.8%, respectively. Excluding the impact of foreign currency and acquisitions, preliminary net sales increased 6.4% in the fourth quarter and 6.1% for the full year. read more

BioMed X – Merck Collaboration in the Field of Selective Kinase Inhibitors Reaches Major Milestone

HEIDELBERG, Germany, January 13, 2016 /PRNewswire/ —

BioMed X Innovation Center and Merck announced today that their collaboration, under which Merck has acquired all generated research and development results in the field of selective kinase inhibitors from BioMed X, has reached a major milestone. In addition, the respective research group at BioMed X is now offering a unique set of bio- and cheminformatics services to research institutes and companies world-wide. read more

Boehringer Ingelheim and Arena Pharmaceuticals Collaborate to Advance Research in Schizophrenia

INGELHEIM, Germany, and SAN DIEGO, Jan. 12, 2016 /PRNewswire/ — Boehringer Ingelheim and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that they have signed an exclusive agreement to conduct joint research to identify drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), which belongs to the group of orphan CNS receptors. An “orphan receptor” is structurally related to a family of proteins that are known to act as functional cell-surface receptors but whose ligand has not yet been identified. read more

Ionis Pharmaceuticals Announces that GSK has Initiated a Phase 1 Study of IONIS-HBV-L Rx

CARLSBAD, Calif., Jan. 13, 2016 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx.  Ionis earned a $1.5 million milestone payment from GSK related to the initiation of this study.  IONIS-HBV-LRx, which was previously referred to as ISIS-GSK6-LRx, is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus (HBV).  IONIS-HBV-LRx incorporates Ionis’ LIgand Conjugated Antisense (LICA) technology that increases drug potency by enhancing delivery of the drug to its target tissue, which for this drug is the liver.  Ionis and GSK are also collaborating on the development of IONIS-HBVRx,  a generation 2.0+ antisense HBV drug.  Both IONIS-HBVRxand IONIS-HBV-LRx are part of Ionis’ alliance with GSK   read more

ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy (PDR)

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease, today announces that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment (PVD) in patients with non-proliferative diabetic retinopathy (NPDR). ThromboGenics hopes to be able to reduce the risk of disease progression to proliferative diabetic retinopathy (PDR) by inducing a total PVD using ocriplasmin. PDR is the major cause of blindness in patients with diabetes. Patients who progress to PDR are at high risk of experiencing severe vision loss or complete blindness. read more

Boston Scientific Launches The LithoVue™ Single-Use Digital Flexible Ureteroscope In U.S. And Europe

PR Newswire, Marlborough, Mass., (January 12, 2016)
Boston Scientific Corporation (NYSE: BSX) today announced the U.S. and European launch of the LithoVue™ Single-Use Digital Flexible Ureteroscope for minimally invasive endoscopic procedures to diagnose and treat stones and other conditions of the kidney, ureter and bladder. By providing a single-use flexible ureteroscope for urologists, the LithoVue System is designed to address the inconsistent performance,1-4 operational challenges and costs associated with widely used reusable scopes that require maintenance, sterilization and reprocessing.1-7  read more

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.